المؤلفون: Hammond D; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Wang SA; Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Konopleva MY; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Kadia TM; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Daver NG; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Ohanian M; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Issa GC; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Alvarado Y; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Short NJ; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Sasaki K; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Lachowiez CA; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Maiti A; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Jabbour EJ; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Takahashi K; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Pierce SR; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., DiNardo CD; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. cdinardo@mdanderson.org.

المصدر: Blood cancer journal [Blood Cancer J] 2023 Sep 21; Vol. 13 (1), pp. 148. Date of Electronic Publication: 2023 Sep 21.

نوع المنشور: Letter; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Bridged Bicyclo Compounds, Heterocyclic*/pharmacology , Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics, Humans ; Sulfonamides/therapeutic use ; Isocitrate Dehydrogenase/genetics

المؤلفون: Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Reville P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., DiNardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Issa G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Patel K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA. NDaver@mdanderson.org.

المصدر: Blood cancer journal [Blood Cancer J] 2022 May 02; Vol. 12 (5), pp. 77. Date of Electronic Publication: 2022 May 02.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Bridged Bicyclo Compounds, Heterocyclic*/pharmacology , Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics, Aged ; Humans ; Prospective Studies ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies ; Sulfonamides ; fms-Like Tyrosine Kinase 3/genetics

المؤلفون: Venugopal S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Masarova L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Issa G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carlos BR; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. cdinardo@mdanderson.org.

المصدر: Blood cancer journal [Blood Cancer J] 2022 Jan 25; Vol. 12 (1), pp. 10. Date of Electronic Publication: 2022 Jan 25.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Aminopyridines/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Azacitidine/*therapeutic use , Isocitrate Dehydrogenase/*genetics , Leukemia, Myeloid, Acute/*drug therapy , Triazines/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Aminopyridines/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azacitidine/adverse effects ; Female ; Humans ; Leukemia, Myeloid, Acute/genetics ; Male ; Middle Aged ; Mutation/drug effects ; Treatment Outcome ; Triazines/adverse effects ; Young Adult

المؤلفون: Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rausch CR; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bose P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thompson PA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Montalbano KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wierda WG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mkonople@mdanderson.org.

المصدر: Blood cancer journal [Blood Cancer J] 2021 Feb 01; Vol. 11 (2), pp. 25. Date of Electronic Publication: 2021 Feb 01.

نوع المنشور: Clinical Trial, Phase II; Letter; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Bridged Bicyclo Compounds, Heterocyclic/*therapeutic use , Decitabine/*therapeutic use , Leukemia, Myeloid, Acute/*drug therapy , Protein Kinase Inhibitors/*therapeutic use , Sulfonamides/*therapeutic use , fms-Like Tyrosine Kinase 3/*antagonists & inhibitors, Adult ; Aged ; Female ; Humans ; Leukemia, Myeloid, Acute/genetics ; Male ; Middle Aged ; Mutation/drug effects ; Treatment Outcome ; fms-Like Tyrosine Kinase 3/genetics